Cannabis and CBD stocks to Watch
This Week
May 14, 2019 -- InvestorsHub NewsWire -- Microcap Speculators --
According to a recent article in The New York Post, major retailers
are "angling for a piece of the exploding CBD
industry, which is expected to more than double to $2.1
billion by next year as consumers pay premium prices for products
to treat maladies ranging from arthritis to ADHD. Till now, the
lion's share of the CBD market has been going to smaller
mom-and-pop shops. But a few bigger chains, including
Walgreens, CVS and GNC, have begun selling CBD-infused topical
creams that treat wrinkles and pain in states where they're
allowed, including New York.
Looking at opportunities in the CBD market for investors to
start researching, Real Brands (USOTC:
RLBD) jumps out. The company gives you all the
benefit of the growing market without some of the risk producers
face. RLBD is a branding company that is growing its
portfolio of CBD brands by the day. The company has strong
management with a solid background in branding and the beverage
industry and plans to expand their holdings focusing on at least
three CBD Categories: smokables, edibles and topical balms
and lotions. The company recently updated their logo and
brand identity. It is also developing an E-Commerce website
and plans to launch it during the early part of the second quarter
(which if you’re paying attention could be any day now) on their
newly acquired domain name, to support online sales of a variety of
smokable, edible, and topical CBD derived from Hemp based products
for each of their brands. Start your research today.
Today we are highlighting: Real Brands,
Inc. (USOTC:
RLBD), Aphria (NYSE:
APHA), HEXO Corp. (AMEX:
HEXO), Auxly Cannabis Group Inc. (CBWTF), and Cara Therapeutics
(NASDAQ:
CARA).
Real Brands, Inc. (USOTC:
RLBD) (Market Cap: $12.488M; Share Price:
$0.0849) is first and foremost a marketing and
branding company, which has been slowly building its portfolio of
trademarked brand names that could each represent on their own
major partnerships and joint ventures going forward.
Jerry Pearring, the CEO of Real Brands commented, “As the demand
for CBD infused products continues to grow, we intend to create
marketing strategies in at least three CBD Categories: smokables,
edibles and topical balms and lotions.”
Products like CBD gums are something which golfers Tiger Woods and
Phil Mickelson are rumored to be chewing. The
non-psychoactive health benefits of CBD are appealing for
golfers.
That’s why RLBD announcing that PGA professional Scott Piercy is
coming aboard as Brand Ambassador is big news. In March ‘19,
he made a further commitment by making a long-term investment into
Real Brands.
RLBD is launching a CBD beverage. The audit on the horizon
means this could also be another major event for investors to pay
attention to. Start your research today.
________
OTHER CANNABIS COS TO RESEARCH INCLUDE:
Aphria Inc. (NYSE: APHA)
(Market Cap: $1.753B; Share Price: $7.01) shares
fell after the Canadian cannabis company reported fiscal
third-quarter results. It posted a C$108.2 million
($81.1 million) loss for its fiscal third quarter, or 43 cents
a share, after a profit of C$12.9 million, or 8 cents a share, in
the same period a year ago. Revenue climbed to C$73.6 million
from C$10.3 million in the first full quarter of Canadian legal
cannabis. But the company sold less cannabis than a year
ago—kilograms sold fell to 2,636.5 from 3,408.9, while the average
retail selling price for medical cannabis increased to C$8.03 per
gram from C$7.51, primarily because of higher oil sales.
In April, it announced that the previously announced take-over
bid (the "Offer") by Green Growth Brands Inc. ("GGB") has failed to
meet the statutory minimum tender condition and has now expired and
is terminated. As previously announced on April 15,
2019, the company entered into a definitive agreement with GGB to
accelerate the expiry date of the Offer to April 25, 2019, as well
as to terminate certain arrangements with GA Opportunities Corp.
("GAOC") for consideration of $89.0 million payable on future dates
as set out in the April 15th press release. The Offer is now
expired and terminated and no longer open to any Aphria shareholder
to tender their shares. Accordingly, GGB will not be taking
up any securities that may have been tendered to the Offer.
GGB will promptly return to the securityholder any Aphria shares
tendered and not withdrawn during the period from the commencement
of the Offer up to the expiry time of the Offer.
________
HEXO Corp (AMEX:
HEXO) (Market Cap: $1.458B; Share Price:
$6.87) and Newstrike Brands Ltd. ("Newstrike")
(TSX-V: HIP) had announced in March that they had entered into
a definitive arrangement agreement (the "Arrangement Agreement")
under which HEXO will acquire all of Newstrike’s issued and
outstanding common shares in an all-share transaction valued at
approximately $263 million. The Transaction
gives HEXO the capacity to produce approximately 150,000
kg of high-quality cannabis annually. The Transaction also
provides HEXO access to four cutting-edge production
campuses totalling close to 1.8 million sq. ft. of near-term
cultivation space and diversified growing and production
techniques. This is in addition to HEXO’s 579,000 sq.
ft. facility for a manufacturing and product development centre of
excellence in Belleville, Ontario. HEXO Corp has its headquarters
in Gatineau Canada, and it produces and sells most of its cannabis
products in the country.
The Brantford, Ontario-based Newstrike Brands were granted a
cultivation license on 16 December 2016, and the company expects
its harvest to be about 42,000 kg of cannabis. Although the company
has not been around for long compared to HEXO, it has high capacity
for cannabis production. HEXO recently announced that it had
completed the first harvest in its 1 million sq. ft. expansion,
marking an important execution milestone in the company's
continuous growth.
HEXO Corp., through its subsidiary, HEXO Operations Inc.,
produces, markets, and sells cannabis in Canada. The company
offers dried cannabis under the Time of Day and H2 lines; Elixir, a
cannabis oil sublingual mist product line; and Decarb, an activated
fine-milled cannabis powder product. It provides its products
under the HEXO and Hydropothecary brand names. The company
serves medical and adult-use markets. As one of the largest
licensed cannabis companies in Canada, HEXO Corp operates with
1.8 million sq. ft of facilities in Ontario and Quebec and a
foothold in Greece to establish a Eurozone processing, production
and distribution center.
_________
Auxly Cannabis Group Inc. (CBWTF) (Market Cap:
$371.291M; Share Price: $0.60425) released its fourth
quarter and full year 2018 financial results in March 2019.
These filings and additional information regarding Auxly are
available for review on SEDAR. For the year ended December
31, 2018, Auxly recognized $747,000 of research revenues from the
recently completed acquisition of KGK in the third quarter of
2018. Auxly realized a gross loss of $188,000 in 2018
comprised of revenues less KGK expenses of $1,078,000 in support of
third-party research contracts.
On April 8, it announced that its wholly-owned subsidiary,
Robinsons Cannabis Inc. ("Robinsons"), has been granted standard
cultivation and processing licenses by Health Canada pursuant to
the Cannabis
Act and Cannabis
Regulations. The licenses give Robinsons the ability
to begin cultivation at its fully constructed 27,700 square-foot
facility in Kentville, Nova Scotia, which was purpose-built to
produce high-quality cannabis.
Auxly Cannabis Group Inc. operates as a cannabis streaming
company. It provides funding for cannabis production; and
holds contractual rights and minority equity interest relating to
the operation of cannabis facilities. The company was
formerly known as Cannabis Wheaton Income Corp. and changed its
name to Auxly Cannabis Group Inc. in June 2018. Auxly
Cannabis Group Inc. was incorporated in 1987 and is headquartered
in Vancouver, Canada.
________
Cara Therapeutics, Inc. (NASDAQ:
CARA) (Market Cap: $734.212M; Share Price:
$18.47), a clinical-stage biopharmaceutical company,
has a comprehensive report issued by Traders News Source, a leading
independent equity research and corporate access firm focused on
small and mid-cap public companies. Cara Therapeutics focuses
on developing and commercializing chemical entities with a primary
focus on pruritus and pain by selectively targeting kappa opioid
receptors.
Cara Therapeutics is a clinical-stage biopharmaceutical company
focused on developing and commercializing new chemical entities
with a primary focus on pruritus by selectively targeting
peripheral kappa opioid receptors (KORs). Cara is developing
a novel and proprietary class of product candidates, led by
KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist
that targets the body's peripheral nervous system, as well as
certain immune cells.
Legal Disclaimer:
This article was written by Regal Consulting, LLC (“Regal
Consulting”). Regal Consulting has agreed to a three-month
term consulting agreement with RLBD dated 8/31/18. The
agreement calls for $100,000 note issued to Regal Consulting, and
2,500,000 restricted 144 shares of RLBD for three months of
service. Regal has elected to convert $73,000 of principal of
the $100,000 note into 2,761,872 Restricted 144 shares of RLBD.
Regal Consulting has agreed to a twelve- month term consulting
agreement with RLBD dated 1/4/2019. The agreement calls for
$10,000 in cash and 500,000 shares per month. All payments were
made directly by Real Brands, Inc. to Regal Consulting, LLC. to
provide investor relations services, of which this article is a
part of. Regal Consulting also paid one thousand dollars cash
to microcapspeculators.com to distribute this article. Regal
Consulting may have a position in the securities mentioned in this
article at the time of publication, and may increase or decrease
its position without notice. This article is based on public
information and the opinions of Regal Consulting. RLBD was given an
opportunity to edit this article. This article contains
forward-looking statements that are subject to certain risks and
uncertainties that could cause actual results to differ materially
from any results predicted herein. Regal Consulting is not
registered with any financial or securities regulatory authority,
and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full
legal disclaimer/
Full Legal Disclaimer Click
Here.
Contact Information:
Company Name: ACR Communication LLC.
Contact Person: Media Manager
Email: info@microcapspeculators.com
Phone: 1-702-720-6310
Country: United States
SOURCE: Microcap Speculators
Real Brands (CE) (USOTC:RLBD)
Historical Stock Chart
From Nov 2024 to Dec 2024
Real Brands (CE) (USOTC:RLBD)
Historical Stock Chart
From Dec 2023 to Dec 2024